Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial
Nat. Med. 2023 Aug 17;[EPub Ahead of Print], Y Lin, NS Raje, JG Berdeja, DS Siegel, S Jagannath, D Madduri, M Liedtke, J Rosenblatt, MV Maus, M Massaro, F Petrocca, A Yeri, O Finney, A Caia, Z Yang, N Martin, TB Campbell, J Rytlewski, J Fuller, K Hege, NC Munshi, JN KochenderferFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.